Health Care & Life Sciences » Pharmaceuticals | Pharmally International Holding Co. Ltd.

Pharmally International Holding Co. Ltd. | Income Statement

Fiscal year is January-December. All values TWD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
3,359
3,944
4,410
4,334
4,305
5,177
Cost of Goods Sold (COGS) incl. D&A
2,091
2,345
2,642
2,606
2,619
3,090
Gross Income
1,268
1,598
1,768
1,728
1,686
2,087
SG&A Expense
447
559
613
622
618
707
EBIT
821
1,039
1,155
1,107
1,067
1,380
Non Operating Income/Expense
8
8
32
37
50
27
Interest Expense
14
7
-
7
31
40
Pretax Income
816
1,043
1,214
1,088
1,116
1,361
Income Tax
208
278
183
182
180
261
Consolidated Net Income
608
766
1,030
905
937
1,100
Net Income
608
766
1,030
903
952
1,114
Net Income After Extraordinaries
608
766
1,030
903
952
1,114
Net Income Available to Common
608
766
1,030
903
952
1,114
EPS (Basic)
9.61
12.10
14.37
12.08
12.71
14.29
Basic Shares Outstanding
63
63
72
75
75
78
EPS (Diluted)
9.61
12.10
14.36
12.08
12.71
14.29
Diluted Shares Outstanding
63
63
72
75
75
78
EBITDA
940
1,161
1,269
1,226
1,217
1,563
Non-Operating Interest Income
1
3
27
25
31
48
Minority Interest Expense
-
-
-
2
15
14

About Pharmally International Holding Co.

View Profile
Address
18th Floor
Taipei TP 11012
Taiwan
Employees -
Website http://www.pharmally.com
Updated 07/08/2019
Pharmally International Holding Co., Ltd. engages in the manufacture and sale of infusion and active pharmaceutical ingredient (API) products. It focuses on basic infusion, infusion therapy, and API. Its products include glucose, sodium chloride, glucose & sodium chloride, compound sodium chloride, lactated ringer's, dextran 40 glucose, dextran 20 glucose, ambroxol hydrochloride & glucose, levofloxacin lactate & sodium chloride injections, nikethamide, dextran powder, and levofloxacin lactate powder.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.